Actively Recruiting
Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia
Led by Fujian Medical University Union Hospital · Updated on 2026-01-30
18
Participants Needed
1
Research Sites
77 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Androgenic Alopecia(AGA) is a highly prevalent condition for which existing pharmacological and surgical interventions present limitations and side effects, creating a clinical need for safer and more effective therapies. In response, human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) have emerged as a cell-free therapeutic strategy. Characterized by their rich bioactive components, absence of tumorigenic risk, and high safety profile, hUCMSC-Exos represent a promising approach for hair regeneration. This study aims to evaluate the safety and efficacy of hUCMSC-Exos combined with automated microneedle delivery for treating AGA. By utilizing innovative lyophilization technology to maintain exosomal bioactivity and employing precision microneedle systems for enhanced delivery, this research seeks to provide a new generation solution for androgenic alopecia treatment.
CONDITIONS
Official Title
Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male aged 18 to 60 years in good general health
- Diagnosed with androgenic alopecia (AGA) with disease duration less than 5 years
- AGA classified as stage II to IV on the Hamilton-Norwood scale at screening
- Able to understand study details and willing to provide written informed consent
- Agree to follow the study protocol and avoid other alopecia treatments during the study
You will not qualify if you...
- Unable or unwilling to provide written informed consent
- History of any cancer within the past 5 years except treated non-scalp basal or squamous cell carcinoma in situ
- Low blood pressure (<90/60 mmHg) within 1 month prior to screening or uncontrolled hypertension within 3 months prior
- Known systemic diseases affecting hair growth or study assessments (e.g., HIV, connective tissue disease, inflammatory bowel disease, hypothyroidism, iron deficiency anemia, malnutrition, syphilis)
- Other types of non-androgenic alopecia (e.g., diffuse alopecia, alopecia areata, cicatricial alopecia)
- History of major organ dysfunction, significant autoimmune disease, or immunodeficiency
- Known bleeding disorders or current use of anticoagulant/antiplatelet therapy except low-dose aspirin
- Chemotherapy, cytotoxic drugs, scalp radiation, or hair restoration surgery within 12 months prior to screening
- History of hair transplantation or need for wigs, hairpieces, or hair bonding agents during the trial
- Severe or multiple drug allergies, atopy, allergy to local anesthetics, or planned desensitization therapy during the study
- Active scalp skin conditions interfering with evaluation (infection, seborrheic dermatitis, psoriasis, eczema, folliculitis, open wounds, scars, atrophy)
- Participation in another interventional clinical trial within 4 weeks prior to screening
- Any medical or psychiatric condition that may affect safety, compliance, or suitability for the study according to investigator judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Affiliated Union Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350001
Actively Recruiting
Research Team
X
xiaosong chen
CONTACT
T
Ting Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here